How long Mounjaro takes to work for obesity treatment, and common side effects

  • Published:
  • Written by the Hiro Clinic Medical Weight Loss editorial team
  • 37 min read
Medically reviewed by Dr. Hiroko Oka Reviewed byDr. Hiroko OkaCertified Member, Japanese Society of Internal Medicine Editorial policy
How long Mounjaro takes to work for obesity treatment, and common side effects

Introduction

In recent years, Mounjaro (generic name: tirzepatide), used as a once-weekly subcutaneous injection, has been drawing attention as a new option for obesity treatment. This drug is a dual agonist that stimulates both “GIP” and “GLP‑1,” and its key feature is that it promotes weight loss through several pathways, including appetite, metabolism and blood sugar. In this article, based on data from clinical trials and real-world practice, we explain in detail and in plain terms how soon Mounjaro starts to take effect after you begin, and which side effects are more likely to occur.

The short answerIf you’re busy, just read this part

  • Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks
  • Side effects are mainly digestive symptoms; serious ones such as gallstones or pancreatitis are rare but require caution
  • The risk of weight regain after stopping is high, so diet, exercise, psychological support and a gradual tapering plan are essential

How long until it starts working: a stage-by-stage guide

1.1 1–2 weeks: early changes

Many people notice a sense that their appetite is being curbed within about 1–2 weeks. This is because Mounjaro acts early on the hormones that control appetite, and it is an important change as the first step toward weight loss .

1.2 4–8 weeks: when weight loss starts to show

Clinical studies often report that “meaningful weight loss” is seen from week 4 onward, particularly around week 8. In general, a 6–8% reduction in body weight is considered possible in the early stage, and depending on the dose, a 5% reduction may be reached at 12–16 weeks.

1.3 3–6 months: the effect becomes fully apparent, with striking changes

Several cases have been reported of 10–20% total body weight loss within 3–6 months of starting treatment. This period is also important as the point at which the effect becomes most evident .
For example, with 72 weeks of continuous treatment, weight loss of about 15% at 5 mg, about 19.5% at 10 mg, and up to about 20.9% at 15 mg was observed .

1.4 Long term (1 year or more): maintaining weight or losing more

As long-term data, in the SURMOUNT-1 trial, a maximum reduction of 23.1% was reached at an average of 22 months, and an average reduction of 19.4% was ultimately maintained. Many (most) participants maintained their weight without regaining 5% or more of their original weight .

Side effect trends and how they change over time

2.1 Digestive symptoms common early on

The most common side effects of Mounjaro are digestive symptoms such as nausea, diarrhea, constipation, vomiting and indigestion.
These are especially noticeable right after starting or right after a dose increase, and tend to ease as the body gradually adjusts .

2.2 Other reactions

Redness or pain at the injection site, fatigue, reduced appetite and abdominal pain have also been reported, but most are mild and mainly temporary .

2.3 Reports of rare serious complications

Although very rare, risks such as pancreatitis, gallstones and thyroid tumors (with many contraindications set by Japan’s Ministry of Health, Labour and Welfare) have been pointed out. However, a clear causal relationship in humans has not been established, and careful monitoring is needed .

There have also been reported cases of vision problems (such as loss of visual field) and problems related to the thyroid, heart and thyroid function, but a causal relationship has not been established .

Summary table: effects and care points by period

PeriodMain effects and reactionsCare points
1–2 weeksAppetite suppression beginsReduce strain on the stomach by staying hydrated and adjusting portion sizes
4–8 weeks6–8% weight loss starts to be seenManaging mild side effects (nausea, diarrhea, etc.) and staying motivated to continue
3–6 monthsWeight loss of 10–20% may be seenEstablishing exercise and eating habits; ongoing care to reduce side effects
1 year or moreSteady maintenance, or further weight loss, is possibleRegular checkups, dose adjustment, reviewing lifestyle and maintaining motivation

Not sure if it suits you? Start with a consultation.

A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.

No consultation fee (first & follow-up visits)Online consultation available

Practical tips for successful treatment

  1. Work closely with your doctor and follow the starting dose and schedule

    Regular evaluations allow the balance between effects and side effects to be adjusted.

  2. Address digestive side effects while they are still mild

    Try strategies such as drinking fluids frequently, eating small frequent meals, choosing gentle foods, and consulting about medication.

  3. Improve lifestyle habits as your weight changes

    Support weight loss with exercise, a protein-focused diet, and good sleep and stress management.

  4. Take a long-term view

    Committing to a steady approach over a year or more is the shortest path to lasting health.

Synergy with lifestyle habits

Mounjaro has a strong weight-loss effect, but rather than relying on the medication alone, combining it with lifestyle habits is the key to success.

Diet

Eating habits centered on high-protein, low-GI foods help maximize the effect of the medication and prevent weight regain.

Exercise

150 minutes of aerobic exercise per week plus strength training twice a week are effective for maintaining basal metabolism and burning fat.

Sleep

Lack of sleep increases the appetite hormone (ghrelin), so getting enough sleep, 7–9 hours, is necessary.

Stress management

Stress can easily lead to overeating and overdrinking; making time for meditation or hobbies helps reduce this risk.

Key point

By using the effect of the medication as a “starting point” to build healthy lifestyle habits, long-term success becomes possible.

Sleep

A closer look at the effects seen in clinical trials

6.1 Results of the SURMOUNT-1 trial

The SURMOUNT-1 trial, conducted mainly in the United States, reported results of giving Mounjaro for 72 weeks to 2,539 adults with obesity or overweight.

5 mg group

Average weight loss of about 15%

10 mg group

Average weight loss of about 19.5%

15 mg group

Average weight loss of up to 20.9%

Key point

Notably, a higher rate of weight loss was observed than with conventional GLP-1 drugs. As a result, Mounjaro is attracting attention as a drug showing “among the largest weight-loss effects achievable with drug therapy.”

6.2 Long-term maintenance

In a later follow-up study, the group that continued for 3 years maintained an average weight loss of 19.4%, showing that when combined with lifestyle improvements, “long-term management is possible while limiting weight regain.”

Differences in effect by patient background

7.1 Differences by sex and age

  • Men have more muscle mass and a higher basal metabolism, so they tend to have a slightly lower rate of weight loss but also less regain.
  • Women, influenced by hormonal balance, often feel the appetite-suppressing effect strongly, and weight loss may be pronounced in the short term.
  • Older adults lose muscle mass more easily, and the risk of sarcopenia (age-related muscle loss) rises along with weight loss, so managing nutrition and exercise is especially important.

7.2 Patients with other conditions

In patients who also have diabetes, blood sugar may improve as well, but care is needed regarding hypoglycemia and digestive symptoms. In patients at risk of cardiovascular disease, weight loss and lower blood pressure are expected to improve the long-term outlook.

Managing the risk of side effects

8.1 Ways to reduce digestive symptoms

Nausea, diarrhea and similar symptoms may be reduced by starting at a low dose and increasing gradually. It has also been reported that avoiding fatty meals and drinking fluids frequently can help ease symptoms.

8.2 Risk of gallstones and pancreatitis

As a risk common to GLP-1 drugs in general, the incidence of gallstones and pancreatitis is known to be slightly higher. If symptoms such as severe abdominal pain or jaundice appear, you need to see a doctor immediately.

8.3 Effects on the thyroid

Rat studies have pointed to an increased risk of thyroid tumors, so people with a history of thyroid disease need to consider its use carefully. Although a clear causal relationship in humans has not yet been established, regular checks by a doctor are recommended.

Not sure if it suits you? Start with a consultation.

A doctor decides whether you can use it and which dose is appropriate, based on your consultation and questionnaire.

No consultation fee (first & follow-up visits)Online consultation available

Preventing weight regain and long-term strategy

9.1 Challenges after stopping

As many studies have shown, when Mounjaro is stopped, appetite returns and weight tends to rebound within a few months. In particular, weight often returns within a year, so a strategy is essential for long-term weight maintenance.

9.2 Specific measures

Diet management

Maintain fullness with high-protein, low-GI meals

Exercise habits

Keep up strength training so your basal metabolism doesn’t drop

Psychological support

Use counseling or group support to ease anxiety about weight regain

Gradual tapering plan

Instead of stopping the medication suddenly, reduce it gradually under a doctor’s guidance

Future research and outlook

GLP-1 drugs, including Mounjaro, are expected to play a major role not only in obesity but also in the prevention and treatment of diabetes and cardiovascular disease. Oral versions (pills) are also being developed, and in the near future it will likely become possible to choose treatments that are easier to continue.

In addition, new drugs such as retatrutide, which also have actions beyond GLP-1, are being developed, and treatment options that are even more potent with fewer side effects are expected to emerge in the future.

About self-pay treatment and off-label use

Self-pay treatment
Medical weight loss is self-pay treatment (paid in full by the patient) and is not covered by public health insurance.
Off-label use
Using medicines for weight management or weight loss may be off-label use, outside the indications approved in Japan.
Relief System for Adverse Drug Reactions
With off-label use, health damage such as a serious side effect may not be covered by Japan’s Relief System for Adverse Drug Reactions.
Individual differences and the doctor’s judgment
Effects and side effects vary from person to person. A doctor decides after a consultation whether you can use a medicine and which medicine and dose are appropriate. Please tell us in advance about any symptoms, chronic conditions or medicines you are taking.

FAQ

QWhen does Mounjaro start to take effect?
A

Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks.

QWhat are the common side effects of Mounjaro?
A

The most common side effects of Mounjaro are digestive symptoms such as nausea, diarrhea, constipation, vomiting and indigestion.

QWill I regain weight if I stop Mounjaro?
A

As many studies have shown, when Mounjaro is stopped, appetite returns and weight tends to rebound within a few months.

QIs there a risk of gallstones or pancreatitis?
A

As a risk common to GLP-1 drugs in general, the incidence of gallstones and pancreatitis is known to be slightly higher.

If symptoms such as severe abdominal pain or jaundice appear, you need to see a doctor immediately.

QDo I need to improve my lifestyle habits rather than relying on the medication alone?
A

Mounjaro has a strong weight-loss effect, but rather than relying on the medication alone, combining it with lifestyle habits is the key to success.

Not sure? Talk to us

No consultation fee (first & follow-up visits)Online consultation available

Toll-free 0120-241-929 (toll-free in Japan, 9:00–18:00 JST, Japanese only)

See prices

Summary

  • Appetite suppression with Mounjaro starts within 1–2 weeks, and visible weight loss appears at 4–8 weeks.
  • Weight loss of 10–20% at 3–6 months is achievable, and with use for a year or more it can be maintained steadily.
  • Side effects are mainly digestive symptoms; serious ones such as gallstones or pancreatitis are rare but require caution.
  • The risk of weight regain after stopping is high, so diet, exercise, psychological support and a gradual tapering plan are essential.
  • Oral medications and drugs with new mechanisms of action are expected to appear, further expanding the options.

Mounjaro is “an obesity medication that combines fast onset with lasting effect,” but to make the most of it, you need to combine it with lifestyle habits under a doctor’s guidance and plan a long-term strategy.

References (evidence)

  • Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022.
  • Aronne LJ, et al. Continued Treatment with Tirzepatide for Maintenance. PMC. 2023.
  • Ghusn W, et al. Weight loss outcomes, tolerability, side effects, and risks. ScienceDirect. 2024. 
  • InstantUC: How Long Does Tirzepatide Take to Work?
  • DrOracle.ai: How long does it take for Mounjaro to take effect? 2025.
  • NEJM: Tirzepatide Compared with Semaglutide for Obesity. May 2025.
  • Wikipedia: Tirzepatide summary. Nature Medicine: GLP-1 receptor agonist safety profile.
  • The Guardian: Long-term SURMOUNT-1 three-year results. 
  • JAMA Ophthalmology reviews (vision risks). 
  • Business Insider: rare thyroid-related complications. 

Who to contact if side effects occur | When to see a doctor

If any of the following symptoms occur, please contact us rather than deciding on your own to wait and see. GIP/GLP-1 receptor agonists, including Mounjaro, are known to cause side effects, mainly digestive symptoms. Most are mild, but serious ones occur in rare cases.

SymptomPossible causeWhat to do
Persistent nausea or vomitingDigestive symptoms; the most common side effectPlease contact us if you remain unable to keep fluids down
Severe abdominal pain (pain radiating to the back)Possible acute pancreatitisStop the medication immediately and see a doctor
Cold sweats, palpitations, intense hunger, or feeling confused or drowsyHypoglycemiaTake sugar right away and contact us
Skin rash, difficulty breathing, or swelling of the face or throatAllergic reactionSee a doctor immediately
Contact: 0120-241-929 (hours 9:00–18:00)

If your symptoms are severe outside our hours, please go to your nearest emergency medical facility.

Each clinic’s direct phone number is listed on the clinic information page.

References

The information about medications in this article is based on the following official sources. For details on dosage and administration and on side effects, always check the latest electronic package insert.
Pharmaceuticals and Medical Devices Agency (PMDA): “Mounjaro Subcutaneous Injection Ateos, electronic package insert”
PMDA: “Drug Guide for Patients: Mounjaro Subcutaneous Injection Ateos” (PDF)
Ministry of Health, Labour and Welfare: “Prevention of lifestyle-related diseases”

When Mounjaro is used for purposes other than obesity disease, it is self-pay treatment and is not covered by Japan’s public health insurance. Effects and side effects vary from person to person.

Reviewing doctor: Hiroko Oka
Reviewing doctor

Hiroko OkaDirector, Hiro Clinic Kawaguchi (physician)

Japanese Society of Internal Medicine Chair, Fukubikai Medical Corporation / Certified Member, Japanese Society of Internal Medicine After graduating from Toho University School of Medicine, she joined the Department of Internal Medicine at Keio University School of Medicine. She gained experience in internal medicine at university and general hospitals, and has been engaged in obesity treatment and weight management guidance from an internal medicine perspective. Certified Occupational Physician, Japan Medical Association. About our medical review and editorial policy

You may also like

Back to all articles

Last updated:

Ask our AI chat AI chat